Irving-based Caris Life Sciences, a leader in AI-driven precision oncology, has filed for an initial public offering. Founded in 2008 by entrepreneur David D. Halbert, Caris was born from a personal mission. Halbert launched the company after witnessing his father’s struggle with cancer, determined to transform diagnosis and treatment by harnessing molecular science and data-driven insights.
In April 2025, just weeks before filing for its IPO, Caris closed a $168 million growth capital round led by life sciences investor Braidwell LP, alongside new investors Perceptive Advisors, Woodline, and Ghisallo, as well as existing backers including Millennium Management and First Light Asset Management. The total raised since its founding in 2018 is $1.86 billion.
Check out Dallas Innovates for the full story.
